Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cell Research

Topics

Biology

Biochemistry

Medicine

Immunology

Pathology

Show all topics

DOI

10.1038/s41422-020-0305-x

License

CC-BY

Other Formats

PDF